- Home
- CCK vs EXEL Comparison
CCK vs EXEL Comparison
Compare CCK & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCK | EXEL |
|---|---|---|
| Founded | 1906 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 12.7B |
| IPO Year | 2003 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CCK | EXEL |
|---|---|---|
| Price | $114.13 | $62.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | ★ $134.93 | $54.87 |
| AVG Volume (30 Days) | 921.3K | ★ 2.1M |
| Earning Date | 10-19-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 79.72 | 57.95 |
| EPS | ★ 3.78 | 1.60 |
| Revenue | ★ $11,665,000,000.00 | $452,477,000.00 |
| Revenue This Year | $10.90 | $10.09 |
| Revenue Next Year | $2.05 | $13.62 |
| P/E Ratio | ★ $30.09 | $39.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $91.31 | $33.76 |
| 52 Week High | $122.91 | $63.31 |
Technical Indicators
Market Signals| Indicator | CCK | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.42 | 66.35 |
| Support Level | $111.22 | $54.38 |
| Resistance Level | $115.48 | N/A |
| Average True Range (ATR) | 1.86 | 1.70 |
| MACD | 1.06 | 0.30 |
| Stochastic Oscillator | 83.02 | 77.71 |
Price Performance
Historical ComparisonAbout CCK Crown Holdings Inc.
Crown Holdings Inc is a producer of metal packaging. The company manufactures beverage cans, metal food cans, and closures, as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.